

Financial news for EGLT dated on 2018-11-19: Egalet Q3 EPS \$(0.93) Misses \$(0.25) Estimate, Sales \$6.651M Miss \$8.35M Estimate

Financial news for EGLT dated on 2018-10-24: 'Trump signs sweeping bill aimed at tackling opioid crisis' - The Hill

Financial news for EGLT dated on 2018-09-23: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for EGLT dated on 2018-09-18: FDA Issues New Safety Measures For Immediate-Release, Extended-Release, and Long-Acting Opioid Analgesics

Financial news for EGLT dated on 2018-08-13: Egalet Corp shares are trading down 13.2% to \$0.31; Not seeing any news or clear catalyst to justify volatility.

Financial news for EGLT dated on 2018-08-08: The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict

Financial news for EGLT dated on 2018-08-08: Egalet Q2 EPS \$(0.22) Beats \$(0.28) Estimate, Sales \$7.4M Miss \$7.99M Estimate

Financial news for EGLT dated on 2018-08-07: Preview: Egalet's Q2 Earnings

Financial news for EGLT dated on 2018-08-07: Egalet Corp shares trading up 36.1% for the session despite no news or clear catalyst to justify price action.

Financial news for EGLT dated on 2018-08-02: 66 Biggest Movers From Yesterday

Financial news for EGLT dated on 2018-08-01: 60 Stocks Moving In Wednesday's Mid-Day Session

Financial news for EGLT dated on 2018-08-01: Egalet Corp. Shares Up 10% On High Volume, Not Seeing Any Co.-Specific News To Justify Move

Financial news for EGLT dated on 2018-07-31: Stocks Which Set New 52-Week Low Yesterday, July 30th

Financial news for EGLT dated on 2018-07-30: Stocks Which Set New 52-Week Low Friday, July 27

Financial news for EGLT dated on 2018-07-27: Stocks Which Set New 52-Week Low Yesterday, July 26th:

Financial news for EGLT dated on 2018-07-20: Stocks Which Set New 52-Week Low Yesterday

Financial news for EGLT dated on 2018-07-19: Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut

Financial news for EGLT dated on 2018-07-03: Benzinga's Daily Biotech Pulse: Titan's Parkinson's Disease Drug Implant Trial, Juniper Pharma Sells Itself At 32% Premium

Financial news for EGLT dated on 2018-05-30: Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immuteq Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA

Financial news for EGLT dated on 2018-05-29: Egalet Announces Large Regional Plan to Cover SPRIX Nasal Spray

Financial news for EGLT dated on 2018-05-07: Egalet Announces National Pharmacy Benefit Manager to Cover SPRIX Nasal Spray, ARYMO ER

Financial news for EGLT dated on 2018-04-17: Egalet Announces Two Large Northeast Regional Health Plans Placed ARYMO ER in Preferred Formulary Position

Financial news for EGLT dated on 2018-04-05: Egalet 8-K Shows Co. Filed Patent Infringement Suit On Apr. 4 Against Teva, For One Of Co.'s ARYMO ER Patents Listed Orange Book, Patent No. '402

Financial news for EGLT dated on 2018-03-19: Egalet Shares Indicated Lower After Hours As Amendment To May 6, '15 Prospectus Shows On Mar. 16, 2018, Prospectus Became Subject To Offering Limits; Co. Is Eligible To Offer, Sell At Least \$16.1M In Common Stock Via Prospectus

Financial news for EGLT dated on 2018-03-13: 46 Biggest Movers From Yesterday

Financial news for EGLT dated on 2018-03-12: 32 Stocks Moving In Monday's Mid-Day Session

Financial news for EGLT dated on 2018-03-12: Egalet Shares Up 13.3% After Co. Earlier

Reported Q4 Revenues Up 21% YoY

Financial news for EGLT dated on 2018-03-12: Egalet Reports Q4 GAAP EPS \$0.03, Sales \$7.8M vs \$7.6M Est.

Financial news for EGLT dated on 2018-03-12: Earnings Scheduled For March 12, 2018

Financial news for EGLT dated on 2018-02-28: Egalet Reports Large Regional Health Plan Placed ARYMO ER, SPRIX Spray In Preferred Formulary Positions

Financial news for EGLT dated on 2018-02-20: Egalet Announces Issuance of New Patent for Guardian Technology

Financial news for EGLT dated on 2018-02-20: Egalet Announces Issuance of New U.S. Patent for Guardian Technology

Financial news for EGLT dated on 2018-01-29: Egalet Reports ARYMO ER Data Published in Current Medical Research and Opinion Journal

Financial news for EGLT dated on 2018-01-23: Egalet Reports Partner OraPharma Has Begun Promoting SPRIX Nasal Spray

Financial news for EGLT dated on 2018-01-22: UPDATE: FDA Page For Egalet's Sprix Updated Jan. 19; Co. Tells Benzinga 'There was a label update that clarified that SPRIX is not for pediatric use...Note SPRIX is indicated for adults only.'

Financial news for EGLT dated on 2018-01-22: Egalet Shares Spike Briefly As Traders Note New Entry Dated Jan. 19th In Supplements Table On FDA Page For Sprix

Financial news for EGLT dated on 2018-01-03: 13G Filing Shows Broadfin Capital Reporting Reduced 9.99% Stake In Egalet; Filing Shows Stake Lowered From 10M Shares to ~4.8M Shares

Financial news for EGLT dated on 2018-01-03: 5 Biggest Price Target Changes For Wednesday

Financial news for EGLT dated on 2018-01-03: Benzinga's Top Upgrades, Downgrades For January 3, 2018

Financial news for EGLT dated on 2018-01-03: Stifel Nicolaus Downgrades Egalet to Hold

Financial news for EGLT dated on 2018-01-03: Egalet Pharma to Partner with a Valeant Subsidiary to Promote SPRIX Nasal Spray in the US

Financial news for EGLT dated on 2017-12-20: Egalet Reduces Debt Obligation From \$61M To \$48.5M

Financial news for EGLT dated on 2017-12-15: Egalet Receives FDA Tentative Approval for Expanded Label for ARYMO ER C-II

Financial news for EGLT dated on 2017-12-06: Egalet Reportedly Notified By CVS Caremark That Sprix Will No Longer Be On Formulary For Caremark's Planned Action Beginning Jan. 2018, Could Impact ~20% Of Sprix Prescriptions

Financial news for EGLT dated on 2017-12-05: Egalet Spikes to High of \$1.25 on Volume

Financial news for EGLT dated on 2017-11-29: 40 Biggest Movers From Yesterday

Financial news for EGLT dated on 2017-11-28: 35 Stocks Moving In Tuesday's Mid-Day Session

Financial news for EGLT dated on 2017-11-28: 30 Stocks Moving In Tuesday's Pre-Market Session

Financial news for EGLT dated on 2017-11-28: A Peek Into The Markets: U.S. Stock Futures Edge Higher Ahead Of Economic Data

Financial news for EGLT dated on 2017-11-28: Egalet Reports its Phase 3 Study of Egalet-002 Met its Primary Endpoint

Financial news for EGLT dated on 2017-11-27: UPDATE: Egalet Says Apotex 'has lost the right to launch an authorized generic version of SPRIX Nasal Spray'

Financial news for EGLT dated on 2017-11-27: Egalet 8-K Shows Co. Is Party To Deal With Apotex Which Permits Potential Launch Of Authorized Generic For SPRIX Nasal Spray In Mar. '18

Financial news for EGLT dated on 2017-11-20: Egalet is Awarded a Grant from

InnoBooster, Terms Not Disclosed

Financial news for EGLT dated on 2017-11-16: Egalet Shares Have Resumed, Off The Highs, Now Up ~55%

Financial news for EGLT dated on 2017-11-16: Egalet Shares Halted On Circuit Breaker, Up 61.45%

Financial news for EGLT dated on 2017-11-16: Egalet Shares Resume Trading, Now Up 61%

Financial news for EGLT dated on 2017-11-16: UPDATE: Egalet's Egalet-002 Was Well Tolerated, Phase 3 Trial Remains On Track For Completion By Year-End

Financial news for EGLT dated on 2017-11-16: Egalet Announces Positive Top-line Phase 3 Safety Study Results For Egalet-002

Financial news for EGLT dated on 2017-11-16: Egalet Shares Halted, News Pending

Financial news for EGLT dated on 2017-11-09: Benzinga's Top Upgrades, Downgrades For November 9, 2017

Financial news for EGLT dated on 2017-11-09: Gabelli & Co. Downgrades Egalet to Hold

Financial news for EGLT dated on 2017-11-08: Egalet Reports Q3 EPS \$(0.46) vs \$(0.45) Est., Sales \$6.7M vs \$7M Est.

Financial news for EGLT dated on 2017-11-06: Egalet Reports ARYMO ER Added to Large Payer Medicare Part D Formulary

Financial news for EGLT dated on 2017-10-26: 22 Stocks To Watch After President Trump Declares Opioid Epidemic A National Health Emergency

Financial news for EGLT dated on 2017-10-26: Pres Trump Implies Top Priority Is Removing Fentanyl From Market

Financial news for EGLT dated on 2017-10-26: Watching Opioid-Related Stocks As Pres Trump Declares America's Opioid Epidemic A National Public Health Emergency

Financial news for EGLT dated on 2017-09-28: FDA Says It Sent Letters To 74 Manufacturers Of Opioid Analgesics Intended For Outpatient Use, Will Soon Issue Guidance For Applicants Seeking Approval For Generic Versions Of Abuse-Deterrent Opioids

Financial news for EGLT dated on 2017-08-09: Egalet Announces Expense Reduction Plan Including Corporate Restructuring

Financial news for EGLT dated on 2017-08-09: Egalet Reports Q2 Loss/Share \$(1.04) vs. \$(1.04) Est., Sales \$6.3M vs. \$6.68M Est.

Financial news for EGLT dated on 2017-07-06: Mid-Afternoon Market Update: L Brands Falls Following Disappointing Sales Report; Herman Miller Shares Surge

Financial news for EGLT dated on 2017-07-06: 15 Biggest Mid-Day Losers For Thursday

Financial news for EGLT dated on 2017-07-06: Mid-Day Market Update: Crude Oil Up Over 2%; Egalet Shares Plummet

Financial news for EGLT dated on 2017-07-06: Mid-Morning Market Update: Markets Open Lower; Liberty Interactive To Acquire HSN

Financial news for EGLT dated on 2017-07-06: Egalet Prices 16,666,667 Share Offering At \$1.80, Accompanying Warrants Exercise Price \$2.70

Financial news for EGLT dated on 2017-07-06: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for EGLT dated on 2017-07-05: Egalet Reports Offering Of Common Stock, Warrants, No Amount Disclosed

Financial news for EGLT dated on 2017-06-20: Mid-Afternoon Market Update: Fang Drops After Q1 Results; Invivo Therapeutics Shares Surge

Financial news for EGLT dated on 2017-06-20: 12 Biggest Mid-Day Losers For Tuesday

Financial news for EGLT dated on 2017-06-20: Mid-Day Market Update: Crude Oil Down Over 3%; Lipocine Shares Spike Higher

Financial news for EGLT dated on 2017-06-20: Mid-Morning Market Update: Markets Open Lower; Lennar Tops Q2 Expectations

Financial news for EGLT dated on 2017-06-20: Egalet Receives Complete Response Letter from FDA for Prior Approval Supplement for 10 mg and 15 mg Dosage Strengths of OXAYDO

Financial news for EGLT dated on 2017-06-08: Companies Holding Shareholder Meetings Today Include: Aerie Pharma, Agile Therapeutics, bluebird bio, Bojangles, Comcast, Clovis Oncology, Etsy, Egalet, Dave And Busters, Ingersoll-Rand, Priceline, Lululemon, Rent-A-Center, Splunk, & Zoe's Kitchen

Financial news for EGLT dated on 2017-06-07: 15 Biggest Mid-Day Losers For Wednesday

Financial news for EGLT dated on 2017-06-07: 22 Stocks Moving In Wednesday's Pre-Market Session

Financial news for EGLT dated on 2017-06-07: Egalet Partners with Ascend Therapeutics to Co-Promote SPRIX Nasal Spray; Payments Not Disclosed

Financial news for EGLT dated on 2017-06-06: Egalet Reports ARYMO ER Will Be Added to One of the Largest Payers in US

Financial news for EGLT dated on 2017-06-05: Egalet Reports Issuance of New U.S. Patent for Guardian Technology Tablet Architecture

Financial news for EGLT dated on 2017-05-17: Egalet Says Data Published in Journal of Opioid Management and American Journal of Drug and Alcohol Abuse; Show Arymo ER Does Not Exhibit Alcohol Dose Dumping; Says Requires Significantly More Effort to Manipulate Than MS Contin

Financial news for EGLT dated on 2017-05-17: Egalet Reports ARYMO ER Data Published in Journal of Opioid Management and American Journal of Drug and Alcohol Abuse

Financial news for EGLT dated on 2017-05-10: Egalet Reports Q1 EPS \$(1.02) vs \$(0.86) Est., Sales \$5.4M vs \$6.9M Est.

Financial news for EGLT dated on 2017-04-18: Egalet Announces FDA Acceptance of File for Prior Approval Supplement for OXAYDO Tablets

Financial news for EGLT dated on 2017-03-30: Egalet Deploys Salesforce to Begin Educating Healthcare Providers about ARYMO ER

Financial news for EGLT dated on 2017-03-29: The FDA News That Put The Wind Beneath Egalet Stock's Wings

Financial news for EGLT dated on 2017-03-29: 18 Biggest Mid-Day Gainers For Wednesday

Financial news for EGLT dated on 2017-03-29: Egalet Surrenders Some Early Gains After Challenging FDA For MorphaBond Exclusivity

Financial news for EGLT dated on 2017-03-29: 22 Stocks Moving In Wednesday's Pre-Market Session

Financial news for EGLT dated on 2017-03-29: Egalet's Challenge to the FDA for MorphaBond Exclusivity is Still Being Considered

Financial news for EGLT dated on 2017-03-23: 15 Biggest Mid-Day Gainers For Thursday

Financial news for EGLT dated on 2017-03-23: 18 Stocks Moving In Thursday's Pre-Market Session

Financial news for EGLT dated on 2017-03-23: Egalet Issued New US and International Patents for Guardian Technology

Financial news for EGLT dated on 2017-03-16: Egalet Says FDA Saw Unintended Consequence Of IV Abuse Potential With Endo's Opana ER

Financial news for EGLT dated on 2017-03-16: UPDATE: Egalet, On Market Potential Of Its ARYMO ER In Light Of FDA Vote On Endo's Opana ER, Highlights to Benzinga ARYMO ER Has IV-Abuse Deterrent Claim, Gelling Properties Resist Passage Through Syringe

Financial news for EGLT dated on 2017-03-16: Egalet, Responding To FDA Panel Vote On Endo's Opana ER, Tells Benzinga Panel Saw Unintended Consequence Of IV Abuse Potential With Opana ER

Financial news for EGLT dated on 2017-03-15: How Endo's FDA Committee Vote Affects Egalet

Financial news for EGLT dated on 2017-03-13: For Egalet, Clinical Delays Outweigh Solid Q4 And Arymo Launch

Financial news for EGLT dated on 2017-03-13: Egalet Gets Grilled On Earnings Call By Unverified Caller

Financial news for EGLT dated on 2017-03-09: Egalet Reports Q4 EPS \$(0.87) vs \$(0.92) Est., Sales \$6.1M vs \$5.1M Est.

Financial news for EGLT dated on 2017-03-06: Egalet Enters Into Drug Product Manufacturing Services Agreement With Halo Pharmaceutical

Financial news for EGLT dated on 2017-01-19: Exclusive: Egalet CEO Talks Drug Approvals, 21st Century Cures Act And Winning The War On Opioid Abuse

Financial news for EGLT dated on 2017-01-18: Egalet CEO Bob Radie Tells Benzinga Mgmt Continues to Evaluate Whether or Not Added Clinical Work on ARYMO to Achieve Abuse-Deterrent Label is Necessary, Says Oral Data Generated May Be Sufficient

Financial news for EGLT dated on 2017-01-12: KemPharm CEO On Recent Results, Catalysts And Prospects: 'ADHD Is By Far The Larger Market Opportunity'

Financial news for EGLT dated on 2017-01-10: 15 Biggest Mid-Day Losers For Tuesday

Financial news for EGLT dated on 2017-01-10: Egalet Shareholders Worried About Limited Use For Newly Approved ARYMO ER

Financial news for EGLT dated on 2017-01-10: Why Egalet Shares Are Plummeting After FDA Approval Of ARYMO ER

Financial news for EGLT dated on 2017-01-10: The Market In 5 Minutes: Altaba, American Apparel And Alabama-Clemson

Financial news for EGLT dated on 2017-01-10: 20 Stocks Moving In Tuesday's Pre-Market Session

Financial news for EGLT dated on 2017-01-09: Egalet Shares Resume, Now Up 4.4% for Session

Financial news for EGLT dated on 2017-01-09: Egalet Shares Halted on Circuit Breaker, Now Down 1.5% for Session

Financial news for EGLT dated on 2017-01-09: Egalet Shares Turn Negative On The Day, Down 1.52%

Financial news for EGLT dated on 2017-01-09: Egalet Shares Up 26% At \$9.87/Share

Financial news for EGLT dated on 2017-01-09: Egalet To Resume Trade At 3:20pm ET

Financial news for EGLT dated on 2017-01-09: Egalet Receives FDA Approval for ARYMO ER, Approval Triggers \$40M From Second Tranche Of Secured Debt Financing

Financial news for EGLT dated on 2017-01-09: Egalet's FDA Approval May Have Triggered Major Short Squeeze

Financial news for EGLT dated on 2017-01-09: FDA Has Approved Egalet's ARYMO ER

Financial news for EGLT dated on 2017-01-09: Egalet Shares Halted Pending News

Financial news for EGLT dated on 2017-01-09: Egalet Shares Jump ~17% Following Word of FDA Approval for ARYMO ER; BZ NOTE: Short Interest in Egalet Was a Massive 61%

Financial news for EGLT dated on 2017-01-09: UPDATE: FDA Approves Egalet's Arymo ER

Financial news for EGLT dated on 2017-01-09: Egalet Shares Spike Higher as Hearing FDA Has Issued Approval for Arymo ER

Financial news for EGLT dated on 2017-01-09: UPDATE: Egalet Says It Plans To Launch ARYMO ER In 15, 30, & 60 mg Doses In Q1 2017

Financial news for EGLT dated on 2017-01-09: Egalet In JPM Healthcare Conf. Presentation Says FDA Has All Info Needed To Take Approval Action

Financial news for EGLT dated on 2016-12-19: Egalet's Best-In-Class Opioid Abuse Deterrent Continues To Impress

Financial news for EGLT dated on 2016-12-19: Analyst Sees Nearly 100% Upside In Egalet Following Latest Clinical Data

Financial news for EGLT dated on 2016-12-16: Here's What Sent Egalet Soaring

Financial news for EGLT dated on 2016-12-16: UPDATE: Egalet-002 Difference In Drug

Liking Between Manipulated Egalet-002 (79.5) Was Significantly Lower Compared To Crushed IR Oxycodone (86.6) With P-Value Of 0.0004

Financial news for EGLT dated on 2016-12-16: Egalet Reports Positive Top-Line Results from an Intranasal Human Abuse Potential Study of Egalet-002

Financial news for EGLT dated on 2016-12-13: 6 Biotechs Still Awaiting December Catalysts

Financial news for EGLT dated on 2016-12-12: Egalet Shares, After Trading Positive At The Open, Moving Lower With Other Biotechs In The Last Hour; Now Down 3.71% On Heavy Volume

Financial news for EGLT dated on 2016-12-08: What Passage Of The 21st Century Cures Act Means For Biotech Stocks

Financial news for EGLT dated on 2016-12-08: Egalet Shares Up 4.69% On Above Average Volume; 21st Century Cures Act Passage Yesterday May Be Viewed As Positive For Companies Developing Products With Opioid Abuse Deterrents

Financial news for EGLT dated on 2016-12-07: 8 Stocks That Rallied For Three Days On Increasing Volume, No News

Financial news for EGLT dated on 2016-12-06: Egalet Wins Patent

Financial news for EGLT dated on 2016-12-01: Egalet Reports Filing of sNDA for OXAYDO

Financial news for EGLT dated on 2016-11-28: Egalet Vs. Ophthotech: Battle Of The December Binary Trades

Financial news for EGLT dated on 2016-11-25: The FDA's Historic Caution On Abuse Deterrent Labeling

Financial news for EGLT dated on 2016-11-17: Egalet Announces OXAYDO Receives Pharmaceutical Composition Patent Protection Through 2024

Financial news for EGLT dated on 2016-11-15: Stifel Healthcare Conference Today

Financial news for EGLT dated on 2016-11-07: Why Egalet Investors Should Expect FDA Approval On Arymo By Year-End

Financial news for EGLT dated on 2016-11-04: Egalet Bottoms Off Its Opening Print

Financial news for EGLT dated on 2016-11-04: Egalet Reports Q3 Results, Offers ARYMO ER Updates

Financial news for EGLT dated on 2016-11-04: Egalet Reports Q3 EPS \$(1.10) vs \$(0.90) Est., Sales \$4.7M vs \$4.6M Est.

Financial news for EGLT dated on 2016-10-31: Egalet Chief Medical Officer Presenting At FDA Public Mtg On Pre-Market Evaluation Of Abuse-Deterrent Properties Of Opioid Drug Products At 11:30am EST

Financial news for EGLT dated on 2016-10-31: FDA Holding Public Mtg On Evaluation Of Abuse-Deterrent Properties Of Opioid Drug Products Oct. 10/31 - 11/1; Presenters Include Teva Pharmaceuticals And Egalet Corp

Financial news for EGLT dated on 2016-10-26: 15 Stocks Which Plummeted Three Days On Increasing Volume

Financial news for EGLT dated on 2016-10-19: Egalet Tells Benzinga 'We Don't Have Any Idea Of Timing' Related To FDA Decision On ARYMO ER; BZ Note: Notable Analyst Tells Benzinga Typical Delay-To-Approval On Opioids Runs 2-4 Weeks

Financial news for EGLT dated on 2016-10-17: Why Egalet's FDA PDUFA Delay Is No Cause For Panic

Financial news for EGLT dated on 2016-10-14: The FDA Missed Egalet's PDUFA Date, But Investors Should Not Be Worried

Financial news for EGLT dated on 2016-10-14: 15 Biggest Mid-Day Losers For Friday

Financial news for EGLT dated on 2016-10-14: Cantor's Russo on Egalet: 'We'd Be Buyers' of Any Weakness at the Open

Financial news for EGLT dated on 2016-10-14: Cantor's Russo Says Most Recent Update on Egalet from FDA 'Fits a Pattern' of Upcoming Favorable FDA Rulings, Believes Co.'s ARYMO ER Could Get Approval Before Dec.

Financial news for EGLT dated on 2016-10-14: Cantor's Chiara Russo Reiterates \$21 Price Target on Egalet, Says 'Has a Lot of Faith in This Product, Faith in This Mgmt'

Financial news for EGLT dated on 2016-10-14: Cantor's Russo on News of Egalet PDUFA Data Delay: 'We See This as Only a Delay'

Financial news for EGLT dated on 2016-10-14: Cantor's Russo Believes Downside in Egalet Shares Today May 'Be Capped Off at ~5%... If [the Stock] Was Down 8%, I'd Be Surprised'

Financial news for EGLT dated on 2016-10-14: Cantor's Chiara Russo on Egalet News from Last Night: 'This is Not Anything to Get All Up in Arms About,' She's Expecting the Name to 'Trade Off a Little, But Not Significantly'

Financial news for EGLT dated on 2016-10-14: 18 Stocks Moving In Friday's Pre-Market Session

Financial news for EGLT dated on 2016-10-14: Cantor Fitzgerald's Chiara Russo Will Be on Benzinga's PreMarket Prep Talking Egalet in ~5 Mins at 8:40 a.m. EDT
premarket.benzinga.com

Financial news for EGLT dated on 2016-10-14: The FDA Won't Meet PDUFA Goal Date For Egalet's ARYMO ER

Financial news for EGLT dated on 2016-10-13: UPDATE: Egalet Says 'Today we were informed that the FDA has identified no particular issue with our application for ARYMO ER...Agency is working on the product label'

Financial news for EGLT dated on 2016-10-13: Egalet Reports FDA Will Not Meet PDUFA Goal Data for ARYMO ER

Financial news for EGLT dated on 2016-10-13: 3 Biotech Catalysts Expected This Week

Financial news for EGLT dated on 2016-10-10: 16 Stocks Moving In Monday's Pre-Market Session

Financial news for EGLT dated on 2016-09-12: Egalet Topline Results Shows OXAYDO Demonstrates Bioequivalence at 15mg Dose

Financial news for EGLT dated on 2016-09-09: Exclusive: Egalet CFO Talks 'Hot Button' Rx Abuse-Deterrence, Pipeline And Multimillion-Dollar Financing

Financial news for EGLT dated on 2016-09-08: Egalet Announces Potential For Intravenous Abuse Deterrent For OXAYDO

Financial news for EGLT dated on 2016-08-05: 25 Biggest Mid-Day Gainers For Friday

Financial news for EGLT dated on 2016-08-05: 22 Stocks Moving In Friday's Pre-Market Session

Financial news for EGLT dated on 2016-08-04: CORRECTION: Egalet Announces The FDA Advisory Committee Recommends the Approval of ARYMO ER

Financial news for EGLT dated on 2016-08-04: Egalet Corporation to Resume Trading at 5:20 PM ET

Financial news for EGLT dated on 2016-08-04: Egalet Shares Halted Ahead of Today's FDA Panel Meeting

Financial news for EGLT dated on 2016-07-19: Egalet Announces 2 Patents For Guardian Technology

Financial news for EGLT dated on 2016-06-28: Egalet Reveals FDA Advisory Committee Meeting For ARYMO ER Extended-Release Tablets

Financial news for EGLT dated on 2016-06-28: Egalet Reports FDA Panel Meeting to be Held on Aug. 4, 2016 to Consider ARYMO ER

Financial news for EGLT dated on 2016-05-23: Egalet Announces Litigation from Purdue Pharma Dismissed

Financial news for EGLT dated on 2016-05-10: Egalet Q1 EPS (\$1.02) vs (\$0.87) est, Revenue \$805K vs \$3.5M est

Financial news for EGLT dated on 2016-04-05: Egalet Releases Corporate Update

Financial news for EGLT dated on 2016-03-24: Egalet Reports Positive Top Line Results for ALERRT Study

Financial news for EGLT dated on 2016-03-24: Egalet Announces Positive Top Line Results for ALERRT Study

Financial news for EGLT dated on 2016-03-14: Janney Capital Initiates Coverage on Egalet at Neutral, Announces \$8.00 PT

Financial news for EGLT dated on 2016-03-08: Egalet Q4 EPS -\$0.28 vs -\$0.91 est, Revenue \$4.2M vs \$2.8M est, May Not Compare

Financial news for EGLT dated on 2016-03-08: Earnings Scheduled For March 8, 2016

Financial news for EGLT dated on 2016-02-29: Egalet Announces FDA Accepts New Drug Application for ARYMO ER Extended-Release Tablets

Financial news for EGLT dated on 2016-02-16: Pozen, Egalet Could be Potential Partners for Struggling Biotech Companies -Reuters

Financial news for EGLT dated on 2016-01-17: 10 Stocks Moving On Friday's After-Hours Session

Financial news for EGLT dated on 2015-12-15: Egalet Announces New Drug Application to FDA For Arymo

Financial news for EGLT dated on 2015-12-14: Egalet Announces Agreement with Teva Pharma To Commercialize Sprix Nasal Spray in Regions Outside US, Egalet to Receive Upfront Payment

Financial news for EGLT dated on 2015-12-04: US Stock Futures Surge; All Eyes On Jobs Report

Financial news for EGLT dated on 2015-12-03: Egalet Terminates Collaboration with Shionogi

Financial news for EGLT dated on 2015-11-04: Egalet Reports Q3 Loss \$0.81 Vs Est Loss \$0.90, Sales \$1.69M Vs Est \$1.62M

Financial news for EGLT dated on 2015-09-10: Egalet Announces Scientific Data at PAINWeek 2015 Meeting Supports Analgesic Efficacy of SPRIX(r) Nasal Spray Versus Commonly Prescribed Oral Combination Opioids in Treatment of Moderate to Severe Short-Term Pain

Financial news for EGLT dated on 2015-09-09: Acura Pharma Announces Co. Egalet Have Commercially Launched US OXAYDO Tablets

Financial news for EGLT dated on 2015-09-09: Egalet Announces Commercial Launch of OXAYDO, the First and Only Immediate-Release Oxycodone Designed to Discourage Intranasal Abuse, and Launch of IMPACT-Rx, a Patient Access Initiative

Financial news for EGLT dated on 2015-08-06: Egalet Q2 EPS -\$1.03 vs -\$1.02 est, Revenue \$0.352M vs \$1.47M est

Financial news for EGLT dated on 2015-07-28: Egalet Prices 6.7M Shares at \$11.25/Share

Financial news for EGLT dated on 2015-07-27: Egalet Reports Public Offering of Common Stock

Financial news for EGLT dated on 2015-06-30: Egalet Announces Positive Top Line Results From Oral Abuse Liability Study For Egalet-002

Financial news for EGLT dated on 2015-06-29: Egalet Announces Positive Top Line Results From Intranasal Study

Financial news for EGLT dated on 2015-06-25: Egalet Reports Co.'s 067-EG-011 Demonstrated Bioequivalence of Egalet-001 60 mg to MS Contin 60 mg

Financial news for EGLT dated on 2015-06-23: Egalet Corp. Announces Will Deploy Specialty Sales Force to Support Promotion of SPRIX Nasal Spray, OXAYDO Oral Tablets

Financial news for EGLT dated on 2015-06-23: Egalet Launches Specialty Pharmaceutical Sales Force

Financial news for EGLT dated on 2015-06-04: Egalet Reports Egalet-002, an Abuse-Deterrent, Extended-Release Oxycodone Product Candidate, Did Not Induce Alcohol Dose Dumping

Financial news for EGLT dated on 2015-05-28: Egalet Category 1 Abuse-Deterrent Studies Demonstrated Strong Abuse-Deterrent Properties of Egalet-002 Compared to Reformulated OxyContin(r)

Financial news for EGLT dated on 2015-05-11: Benzinga's Top Initiations

Financial news for EGLT dated on 2015-05-11: Guggenheim Securities Initiates Coverage on Egalet at Buy, Announces \$24.00 PT

Financial news for EGLT dated on 2015-05-07: Egalet Q1 EPS -\$1.02 vs -\$0.75 est

Financial news for EGLT dated on 2015-03-17: Egalet Earns \$10 Milestone Payment Triggered by Advancement of Shionogi's S-718632, Using Egalet's Guardian Technology

Financial news for EGLT dated on 2015-03-16: Egalet Reports FY 2014 Loss/Share \$(2.97) vs \$(3.27) Est; Revenue \$1.92M vs \$900K Est

Financial news for EGLT dated on 2015-03-16: Earnings Scheduled For March 16, 2015

Financial news for EGLT dated on 2015-01-22: Egalet Announces Positive Top-Line Results from Oral Human Abuse Liability Study of Egalet-001

Financial news for EGLT dated on 2015-01-22: Egalet Announces Positive Top-Line Results From Oral Human Abuse Liability Study of Abuse-Deterrent Morphine, Egalet-001

Financial news for EGLT dated on 2014-11-12: Egalet Reports Q3 EPS of \$(0.63) vs \$(0.77) Est

Financial news for EGLT dated on 2014-09-24: Stocks Gain While Dollar Reaches Highest Level Since 2010

Financial news for EGLT dated on 2014-09-24: Dow Jumps 170 Points; Bed Bath & Beyond Shares Rise On Upbeat Results

Financial news for EGLT dated on 2014-09-24: UPDATE: Stifel Reiterates, Lowers Price Target On Egalet Corp As Filing Delay Is Likely

Financial news for EGLT dated on 2014-09-24: Morning Market Losers

Financial news for EGLT dated on 2014-09-23: Egalet Announces Update On Clinical Development Plan For Abuse-Deterrent Morphine Egalet-001

Financial news for EGLT dated on 2014-09-11: Egalet Announces Issuance Of US Patent

Financial news for EGLT dated on 2014-08-18: Egalet Announces Successful Meeting With FDA Following Phase 2 Trial For Egalet-002

Financial news for EGLT dated on 2014-08-06: Egalet Announces Topline Results From Bioequivalence Studies of Abuse-Deterrent Morphine, Egalet-001

Financial news for EGLT dated on 2014-07-15: Egalet Announces Positive Top Line Results For Egalet-001

Financial news for EGLT dated on 2014-05-13: Egalet Reports Q1 EPS of \$(1.34)

Financial news for EGLT dated on 2014-05-12: Morning Market Losers

Financial news for EGLT dated on 2014-05-12: Shares of Egalet Corp. Resume Following Circuit Breaker, Stock Down ~14%

Financial news for EGLT dated on 2014-04-01: Egalet Added to Russell 3000, Russell 2000 and Russell Global Indexes

Financial news for EGLT dated on 2014-03-25: Egalet Begins Bioequivalence Studies for Egalet-001, Sees Submitting NDA in Q4'14, Will Introduce During 2H of 2015 if FDA Approves

Financial news for EGLT dated on 2014-03-10: Afternoon Gainers for March 10th

Financial news for EGLT dated on 2014-03-05: Canaccord Genuity Initiates Coverage on Egalet at Buy, Announces \$20.00 PT

Financial news for EGLT dated on 2014-03-03: Stifel Nicolaus Initiates Coverage on Egalet at Buy, Announces \$20.00 PT

Financial news for EGLT dated on 2014-03-03: Janney Capital Initiates Coverage on Egalet at Buy, Announces \$30.00 PT

Financial news for EGLT dated on 2014-03-03: Benzinga's Top Initiations

Financial news for EGLT dated on 2014-03-03: JMP Securities Initiates Coverage on Egalet at Market Outperform, Announces \$19.00 PT

Financial news for EGLT dated on 2014-02-06: Shares of Egalet Moving Lower Following Open at \$12.50, Now Around \$12, Priced at \$12/Share

Financial news for EGLT dated on 2014-02-06: Waiting on Several IPO's This Morning: LADR, EGLT, CMFN, EBIO, RVNC